Gonzalo Sapisochin

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2168543/gonzalo-sapisochin-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123
papers2,906
citations24
h-index52
g-index143
ext. papers4,285
ext. citations4.8
avg, IF5.49
L-index

#	Paper	IF	Citations
123	Attitudes of Canadian Colorectal Cancer Care Providers towards Liver Transplantation for Colorectal Liver Metastases: A National Survey <i>Current Oncology</i> , 2022 , 29, 602-612	2.8	
122	Systematic Review and Meta-Analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	1
121	Outcomes of Adult Liver Retransplantation: A Canadian National Database Analysis <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022 , 2022, 9932631	2.8	
120	Perioperative fluid management and outcomes in adult deceased donor liver transplantation - a systematic review of the literature and expert panel recommendations <i>Clinical Transplantation</i> , 2022 , e14651	3.8	О
119	ASO Visual Abstract: Systematic Review and Meta-analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	
118	Dynamic risk profiling of hepatocellular carcinoma recurrence after curative intent liver resection <i>Hepatology</i> , 2022 ,	11.2	2
117	ASO Author Reflections: Searching for Prognostic Factors of Early Recurrence in Intrahepatic Cholangiocarcinoma <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	
116	De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference <i>Transplantation</i> , 2022 , 106, e30-e	45 ⁸	3
115	Reply to: Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma <i>Hepatology</i> , 2022 ,	11.2	
114	Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation-Adjusting the Odds?. <i>Transplant International</i> , 2022 , 35, 10333	3	
113	Outcomes of Highly Selected Live Donors With a Future Liver Remnant Less Than or Equal to 30%: A Matched Cohort Study. <i>Transplantation</i> , 2021 , 105, 2397-2403	1.8	2
112	Superior long-term outcome of Adult Living Donor Liver Transplantation A cumulative single-center cohort study with 20 years follow-up. <i>Liver Transplantation</i> , 2021 ,	4.5	3
111	Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan. <i>Clinical Proteomics</i> , 2021 , 18, 27	5	O
110	The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach. <i>Liver Transplantation</i> , 2021 ,	4.5	4
109	Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. <i>Annals of Surgery</i> , 2021 , 273, 483-493	7.8	11
108	Blood Cell Salvage and Autotransfusion Does Not Worsen Oncologic Outcomes Following Liver Transplantation with Incidental Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6816-6825	3.1	1
107	Novel biomarker for hepatocellular carcinoma: high tumoral PLK-4 expression is associated with better prognosis in patients without microvascular invasion. <i>Hpb</i> , 2021 , 23, 359-366	3.8	

106	Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. <i>Radiotherapy and Oncology</i> , 2021 , 156, 120-126	5.3	9
105	Dual-Specificity Phosphatase 9 Regulates Cellular Proliferation and Predicts Recurrence After Surgery in Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2021 , 5, 1310-1328	6	3
104	Enhanced Recovery for Liver Transplantation: A First Step on a Long Road. <i>Transplantation</i> , 2021 ,	1.8	2
103	Re: Hepatobiliary Scintigraphy to Increase the Safety in Right Lobe Living Donor Liver Transplantation: Not Just a Matter of Age and Remnant Volume. <i>Transplantation</i> , 2021 , 105, e64	1.8	
102	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 1002	. 60 0.3	11
101	Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021 , 74, 483-490	11.2	16
100	Reply to "Reducing the Safety Limit for Remnant Liver Volume in Living Donor Hepatectomy: Are We Pushing the Envelope Off the Edge?". <i>Transplantation</i> , 2021 , 105, e62	1.8	0
99	Dynamic Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2021 , 156, 559-567	5.4	2
98	Early Allograft Dysfunction After Liver Transplantation With Donation After Circulatory Death and Brain Death Grafts: Does the Donor Type Matter?. <i>Transplantation Direct</i> , 2021 , 7, e727	2.3	О
97	Comment on "Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases": What if Those Lesions are Gone?. <i>Annals of Surgery</i> , 2021 , 274, e101	7.8	1
96	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021 , 21, 475-483	8.7	13
95	Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation. <i>Abdominal Radiology</i> , 2021 , 46, 1572-1585	3	1
94	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021 , 21, 460-474	8.7	20
93	Expert Consensus Guidelines on Minimally Invasive Donor Hepatectomy for Living Donor Liver Transplantation From Innovation to Implementation: A Joint Initiative From the International Laparoscopic Liver Society (ILLS) and the Asian-Pacific Hepato-Pancreato-Biliary Association	7.8	16
92	Perihilar Cholangiocarcinoma - Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. <i>Annals of Surgery</i> , 2021 , 274, 780-788	7.8	10
91	Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. <i>Transplant International</i> , 2021 , 34, 1444-1454	3	1
90	Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. <i>JAMA Surgery</i> , 2021 , 156, e213112	5.4	4
89	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021 , 27, 1767-1778	4.5	3

88	Liver transplantation for colorectal liver metastasis: aiming for a cure or a palliation?. <i>Transplant International</i> , 2021 , 34, 2004-2005	3	O
87	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 933-946	18.8	6
86	Bridging Therapy for Liver Transplantation 2021 , 215-224		
85	The intersection of harm reduction and postoperative care for an illicit fentanyl consumer after major surgery: A case report. <i>Canadian Journal of Pain</i> , 2021 , 5, 166-171	1.5	
84	A Pre-TACE Radiomics Model to Predict HCC Progression and Recurrence in Liver Transplantation: A Pilot Study on a Novel Biomarker. <i>Transplantation</i> , 2021 , 105, 2435-2444	1.8	1
83	Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. Journal of Clinical Medicine, 2020 , 9,	5.1	7
82	Center Experience Affects Liver Transplant Outcomes in Patients with Hilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5209-5221	3.1	12
81	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 765-775	18.8	19
80	Renal Dysfunction After Liver Transplantation: Effect of Donor Type. <i>Liver Transplantation</i> , 2020 , 26, 799-810	4.5	8
79	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 649-657	18.8	38
78	Liver resection and transplantation for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020 , 72, 364-377	13.4	56
77	Preoperative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC) <i>Journal of Clinical Oncology</i> , 2020 , 38, 571-571	2.2	
76	Predicting Liver Transplant Patient Outcomes. Is a Validated Model Enough?. <i>Transplantation</i> , 2020 , 104, 2469-2470	1.8	
75	Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: A review of the general principles. <i>International Journal of Surgery</i> , 2020 , 82S, 77-81	7.5	8
74	Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival. <i>Transplantation</i> , 2020 , 104, 2105-2112	1.8	18
73	Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020 , 104, 1131-1135	1.8	13
72	Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020 , 104, 1136-1142	1.8	27
71	The ILTS Consensus Conference on Transplant Oncology: Setting the Stage. <i>Transplantation</i> , 2020 , 104, 1119-1120	1.8	5

(2019-2020)

70	Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020 , 104, 1143-1149	1.8	10
69	Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020 , 104, 1125-1130	1.8	26
68	The AuthorsPReply: Tacrolimus Trough Concentrations After Liver Transplantation: Back to the Future. <i>Transplantation</i> , 2020 , 104, e115-e116	1.8	
67	Posttransplant Calcineurin Inhibitors Levels and Intrapatient Variability Are Not Associated With Long-term Outcomes Following Liver Transplantation. <i>Transplantation</i> , 2020 , 104, 1201-1209	1.8	O
66	Recent developments and ongoing trials in transplant oncology. Liver International, 2020, 40, 2326-2344	1 7.9	2
65	Artificial intelligence in transplantation (machine-learning classifiers and transplant oncology). <i>Current Opinion in Organ Transplantation</i> , 2020 , 25, 426-434	2.5	5
64	Response to: "Surgical Volume Alone Does Not Determine Outcome Following Liver Transplant for Perihilar Cholangiocarcinoma". <i>Annals of Surgical Oncology</i> , 2020 , 27, 932-933	3.1	
63	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , 2020 , 104, 2087-2096	1.8	7
62	Surgery for Biliary Cancer 2020 , 545-553		
61	Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. <i>Hepatology</i> , 2020 , 71, 569-582	11.2	17
60	Recent advances in liver transplantation for cancer: The future of transplant oncology. <i>JHEP Reports</i> , 2019 , 1, 377-391	10.3	15
59	Liver Transplantation for Acute Liver Failure Due to Dengue Fever. <i>Hepatology</i> , 2019 , 70, 1863-1865	11.2	6
58	Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. <i>Abdominal Radiology</i> , 2019 , 44, 1795-1807	3	18
57	Downstaging and Expanded Criteria Hepatocellular Carcinoma Liver Transplantation. <i>Current Hepatology Reports</i> , 2019 , 18, 400-407	1	2
56	Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion Journal of Clinical Oncology, 2019 , 37, 428-428	2.2	
55	An updated retrospective review of the safety and efficacy of sorafenib for recurrent hepatocellular carcinoma post-liver transplantation <i>Journal of Clinical Oncology</i> , 2019 , 37, 313-313	2.2	
54	Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 2136-2143	1.8	2
53	How far can we go with hepatocellular carcinoma in living donor liver transplantation?. <i>Current Opinion in Organ Transplantation</i> , 2019 , 24, 644-650	2.5	7

52	The Impact of Preexisting and Post-transplant Diabetes Mellitus on Outcomes Following Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 2523-2530	1.8	24
51	Serum Factor V Is a Continuous Biomarker of Graft Dysfunction and a Predictor of Graft Loss After Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 944-951	1.8	9
50	Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. <i>Hpb</i> , 2019 , 21, 731-738	3.8	15
49	What is transplant oncology?. Surgery, 2019, 165, 281-285	3.6	30
48	Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. <i>Journal of Hepatology</i> , 2019 , 70, 866-873	13.4	51
47	Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. <i>Journal of Hepatology</i> , 2019 , 70, 666-673	13.4	35
46	Reply. Liver Transplantation, 2018 , 24, 441	4.5	
45	Expanding the donor pool: Donation after circulatory death and living liver donation do not compromise the results of liver transplantation. <i>Liver Transplantation</i> , 2018 , 24, 779-789	4.5	42
44	Time to reconsider liver transplantation for intrahepatic cholangiocarcinoma?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 294-295	18.8	3
43	Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. <i>Transplantation</i> , 2018 , 102, 640-647	1.8	29
42	Liver Transplantation is Equally Effective as a Salvage Therapy for Patients with Hepatocellular Carcinoma Recurrence Following Radiofrequency Ablation or Liver Resection with Curative Intent. <i>Annals of Surgical Oncology</i> , 2018 , 25, 991-999	3.1	20
41	Surgical Complications after Right Hepatectomy for Live Liver Donation: Largest Single-Center Western World Experience. <i>Seminars in Liver Disease</i> , 2018 , 38, 134-144	7.3	23
40	Current status of liver transplantation for cholangiocarcinoma. <i>Liver Transplantation</i> , 2018 , 24, 294-303	4.5	55
39	Defining Benchmarks in Liver Transplantation: A Multicenter Outcome Analysis Determining Best Achievable Results. <i>Annals of Surgery</i> , 2018 , 267, 419-425	7.8	90
38	Baseline anemia in patients with biliary tract cancer (BTC) and its association with survival: A retrospective cohort study <i>Journal of Clinical Oncology</i> , 2018 , 36, 426-426	2.2	1
37	ASO Author Reflections: Salvage Liver Transplant for Recurrent Hepatocellular Carcinoma After Treatments With Curative Intent. <i>Annals of Surgical Oncology</i> , 2018 , 25, 794-795	3.1	1
36	Living Donor Liver Transplantation Using Selected Grafts With 2 Bile Ducts Compared With 1 Bile Duct Does Not Impact Patient Outcome. <i>Liver Transplantation</i> , 2018 , 24, 1512-1522	4.5	16
35	Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. <i>Seminars in Radiation Oncology</i> , 2018 , 28, 295-308	5.5	3

(2016-2018)

34	Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. <i>Nature Communications</i> , 2018 , 9, 4383	17.4	452
33	Splenectomy as Flow Modulation Strategy and Risk Factors of De Novo Portal Vein Thrombosis in Adult-to-Adult Living Donor Liver Transplantation. <i>Liver Transplantation</i> , 2018 , 24, 1209-1220	4.5	12
32	Live donor liver transplantation with older donors: Increased long-term graft loss due to HCV recurrence. <i>Clinical Transplantation</i> , 2018 , 32, e13304	3.8	2
31	The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018 , 2018, 9531925	2.8	31
30	Reply. <i>Hepatology</i> , 2017 , 65, 1778	11.2	
29	Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. <i>Journal of Hepatology</i> , 2017 , 67, 92-99	13.4	144
28	Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1843-1851	3.1	10
27	Mixed hepatocellular and cholangiocarcinoma: the difficulty of finding the right answer. <i>Hpb</i> , 2017 , 19, 558	3.8	1
26	Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 203-217	24.2	196
25	Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. <i>Transplant International</i> , 2017 , 30, 1140-1149	3	10
24	Preserving the Pancreas Graft: Outcomes of Surgical Repair of Duodenal Leaks in Enterically Drained Pancreas Allografts. <i>Transplantation Direct</i> , 2017 , 3, e179	2.3	8
23	Reply. <i>Hepatology</i> , 2017 , 66, 1704-1705	11.2	
22	Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. <i>Cancer Medicine</i> , 2017 , 6, 2017-2033	4.8	12
21	Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. <i>JAMA Oncology</i> , 2017 , 3, 493-500	13.4	148
20	Avoiding ICU Admission by Using a Fast-Track Protocol Is Safe in Selected Adult-to-Adult Live Donor Liver Transplant Recipients. <i>Transplantation Direct</i> , 2017 , 3, e213	2.3	7
19	Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. <i>PLoS ONE</i> , 2017 , 12, e0185198	3.7	15
18	Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer, 2016, 6, 34-43	9.1	34
17	The use of stereotactic body radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma <i>Journal of Clinical Oncology</i> , 2016 , 34, 418-418	2.2	3

16	Right lobe living-donor hepatectomy-the Toronto approach, tips and tricks. <i>Hepatobiliary Surgery and Nutrition</i> , 2016 , 5, 118-26	2.1	7
15	Live Donor Liver Transplantation With Older (50 Years) Versus Younger (. <i>Annals of Surgery</i> , 2016 , 263, 979-85	7.8	22
14	Normothermic ex vivo liver perfusion using steen solution as perfusate for human liver transplantation: First North American results. <i>Liver Transplantation</i> , 2016 , 22, 1501-1508	4.5	128
13	The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. <i>Hepatology</i> , 2016 , 64, 2077-2088	11.2	169
12	The significance of pre-operative coronary interventions on outcome after pancreas transplantation. <i>Clinical Transplantation</i> , 2016 , 30, 233-40	3.8	1
11	Defining Benchmarks for Major Liver Surgery: A multicenter Analysis of 5202 Living Liver Donors. <i>Annals of Surgery</i> , 2016 , 264, 492-500	7.8	98
10	Conservative Pancreas Graft Preservation at the Extreme. <i>Transplantation Direct</i> , 2016 , 2, e50	2.3	3
9	Long-term results of pancreaticoduodenectomy with superior mesenteric and portal vein resection for ductal adenocarcinoma in the head of the pancreas. <i>Cirugā Espaāla</i> , 2015 , 93, 522-9	0.7	9
8	Should We Exclude Live Donor Liver Transplantation for Liver Transplant Recipients Requiring Mechanical Ventilation and Intensive Care Unit Care?. <i>Transplantation Direct</i> , 2015 , 1, e30	2.3	5
7	Liver transplantation for cholangiocarcinoma: Current status and new insights. <i>World Journal of Hepatology</i> , 2015 , 7, 2396-403	3.4	32
6	Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. <i>Liver Transplantation</i> , 2014 , 20, 945-51	4.5	170
5	Management of "very early" hepatocellular carcinoma on cirrhotic patients. <i>World Journal of Hepatology</i> , 2014 , 6, 766-75	3.4	15
4	Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis. <i>Annals of Surgical Oncology</i> , 2013 , 20, 1194-202	3.1	68
3	Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centre. <i>Hepatology International</i> , 2011 , 5, 707-15	8.8	14
2	Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. <i>Liver Transplantation</i> , 2011 , 17, 934-42	4.5	123
1	Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. <i>World Journal of Surgery.</i> 2010 . 34, 2146-54	3.3	19